

BC Cancer ST Program Updates for July 2025

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer Sites (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version
 - **Do not** use the Copy Forward functionality to ensure that the updates apply



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

Protocols: LUAVATZ and LUSCATPE

Cycles/PowerPlans: All treatment PowerPlans

Chemotherapy phase:

For all PowerPlans, below Zero Time order, the following changes have been made:

- **Added Yellow Clinical Decision Support note:** *Select one atezolizumab option:*
- **Added** atezolizumab subcut - oncology order: *1,875 mg, subcutaneous, once oncology, administer over: 7 minutes, drug form: syringe-inj.*
 - This order is mutually exclusive with IV option with neither option preselected.
 - Order comment for Cycle 1 PowerPlan: *Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration.*

Select one atezolizumab option:

<input type="checkbox"/>	atezolizumab (atezolizumab subcut - oncology)	1,875 mg, subcutaneous, once oncology, administer over: 7 minute, drug form: syringe-inj	Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration
<input type="checkbox"/>	atezolizumab (atezolizumab - oncology)	1,200 mg, IV, once oncology, administer over: 60 minute, drug form: bag	Day 1

- Order comment for Cycle 2+ PowerPlan: *Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration. Discontinue observation after 3 consecutive treatments with no reaction.*

Select one atezolizumab option:

<input type="checkbox"/>	atezolizumab (atezolizumab subcut - oncology)	1,875 mg, subcutaneous, once oncology, administer over: 7 minute, drug form: syringe-inj	Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration. Discontinue observation after 3 consecutive treatments with no reaction
<input type="checkbox"/>	atezolizumab (atezolizumab - oncology)	1,200 mg, IV, once oncology, administer over: 30 minute, drug form: bag	Day 1

- **Changed** 'Bilirubin' to 'Total Bilirubin' in pre-chemo metrics.

Total Bilirubin Less Than or Equal to 1.5 x ULN within 96 hours

Versioning: Yes

Jira: CST-319814

Protocols: GIATZB

Cycles/PowerPlans: All treatment PowerPlans

Chemotherapy phase:

For all PowerPlans, below Zero Time order, the following changes have been made:

- **Added Yellow Clinical Decision Support** note: *Select one atezolizumab option:.*
- **Added** atezolizumab subcut - oncology order: *1,875 mg, subcutaneous, once oncology, administer over: 7 minute, drug form: syringe-inj.*
 - This order is mutually exclusive with IV option with neither option preselected.
 - Order comment for Cycle 1 PowerPlan: *Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration*

Select one atezolizumab option:

<input type="checkbox"/>	atezolizumab (atezolizumab subcut - oncology) 1,875 mg, subcutaneous, once oncology, administer over: 7 minute, drug form: syringe-inj Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration
<input type="checkbox"/>	atezolizumab (atezolizumab - oncology) 1,200 mg, IV, once oncology, administer over: 60 minute, drug form: bag Day 1

- Order comment for Cycle 2+ PowerPlan: *Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration. Discontinue observation after 3 consecutive treatments with no reaction.*

Select one atezolizumab option:

<input type="checkbox"/>	atezolizumab (atezolizumab subcut - oncology) 1,875 mg, subcutaneous, once oncology, administer over: 7 minute, drug form: syringe-inj Subcutaneous Injection: Inject into thigh. Observe for 15 minutes after administration. Discontinue observation after 3 consecutive treatments with no reaction
<input type="checkbox"/>	atezolizumab (atezolizumab - oncology) 1,200 mg, IV, once oncology, administer over: 30 minute, drug form: bag Day 1

- Changed 'Bilirubin' to 'Total Bilirubin' in pre-chemo metrics.

Total Bilirubin Less Than or Equal to 1.5 x ULN within 96 hours

Versioning: Yes

Jira: CST-319810

Protocols: LYPALL

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Prescription Phase:

- **Added** new fixed doses to cyclophosphamide PO order as drop-down options (no dose calculator required):
 - 100 mg, PO, qdaily, drug form: tab, dispense qty: 30 day
 - 100 mg, PO, qdaily, drug form: tab, dispense qty: 60 day
 - 100 mg, PO, qdaily, drug form: tab, dispense qty: 90 day

ONCP LY LYPALL Oral Medications - Cycle 1, Prescriptions (Future Pending)

Link to Protocol: Lymphoma Palliative Chemotherapy

Pre-Chemo Metrics

- Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$ within 72 hours
- Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 72 hours
- If using methotrexate:
 - Creatinine Clearance Greater Than or Equal to 80 mL/min within 72 hours
 - If using procarbazine:
 - Alanine Aminotransferase Less Than or Equal to 5 x ULN within 72 hours
 - Bilirubin Less Than 25 micromol/L within 72 hours

Treatment Regimen

<input type="checkbox"/>	prednisONE	mg, PO, as directed, Take on Days ____ in the morning, drug form: tab, day
<input type="checkbox"/>	dexamethasone	mg, PO, as directed, Take on Days ____, drug form: tab, day
	Usual dose for cyclophosphamide: 200 to 450 mg/m ² /day. Refer to protocol for dosing guidelines	
<input type="checkbox"/>	cyclophosphamide	300 mg/m ² , PO, as directed, Take daily on Days ____, drug form: tab, day Round dose to nearest 25 mg
	Usual dose for methotrexate: 15 to 25 mg/m ² twice weekly. Refer to protocol for dosing guidelines	
<input type="checkbox"/>	methotrexate	300 mg/m ² , PO, as directed, Take daily on Days ____, drug form: tab, day 100 mg, PO, qdaily, drug form: tab, dispense qty: 30 day 100 mg, PO, qdaily, drug form: tab, dispense qty: 60 day 100 mg, PO, qdaily, drug form: tab, dispense qty: 90 day
	Usual dose for etoposide: 50 to 300 mg/m ² /day. Refer to protocol for dosing guideline	
<input type="checkbox"/>	etoposide	

ONCP LY LYPALL Oral Medications (Pending)

► Show additional details

+ Add Document Response View Responses

ONCP LY LYPALL Pretreatment Plan

Start

ONCP LY LYPALL Oral Medications

Versioning: Yes

Jira: CST-314114

Protocols: ULYOGLOFIT

Cycles/PowerPlans: All associated PowerPlans and Regiments

Changes to the following ULYOGLOFIT PowerPlans:

- ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 8
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 15
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 2
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 3+
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 1 Day 1
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 1 Day 15
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 2
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 3
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 4+

Chemotherapy Phase:

- Clinical Decision Support note updated: *Link to Protocol: Treatment of Lymphoma using oBINutuzumab and Glofitamab.*

ONCP LY ULYOGLOFIT (Outpatient) Cycle 1 Day 1 - Cycle 1, Chemotherapy (Day 1) (Future Pending)		
		Day 1
		Future Pending
		*Est. 21-Jun-2025 08:0...
		Actions ▾
	Link to Protocol: Treatment of Lymphoma using oBINutuzumab and Glofitamab	
	Pre-Medications	
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
<input checked="" type="checkbox"/>	dexamethasone 20 mg, IV, once oncology, drug form: inj 60 minutes prior to oBINutuzumab. Day 1	-60 min Planned
<input checked="" type="checkbox"/>	acetaminophen ▾ 650 mg, PO, once oncology, drug form: tab, Use Patient ... 30 minutes prior to oBINutuzumab. Day 1	-30 min Planned
<input checked="" type="checkbox"/>	diphenhydrAMINE ▾ 50 mg, PO, once oncology, drug form: cap, Use Patient ... 30 minutes prior to oBINutuzumab. Day 1	-30 min Planned
	If hypersensitivity reactions have occurred, see protocol or BC Cancer hypersensitivity guidelines (SCDRUGRX) for additional pre-medications	

Changes to the ONC LY ULYOGLOFIT (Inpatient) and ONC LY ULYOGLOFIT (Outpatient) Regimens:

- **Update description to:** *Treatment of Lymphoma using oBINutuzumab and Glofitamab.*

ONC LY ULYOGLOFIT (Inpatient) (Pending)

▼ Hide additional details

Regimen description:

Treatment of Lymphoma using oBINutuzumab and Glofitamab

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

Document Response

View Responses

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

ONCP LY ULYOGLOFIT Pretreatment Plan

*Est. Start Date: **/**/****

Start

Skip

	ONCP LY ULYOGLOFIT (Outpatient) Cycle 1 Day 1 - Cycle 1	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 8 - Cycle 1	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 15 - Cycle 1	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycle 2 - Cycle 2	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 3	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 4	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 5	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 6	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 7	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 8	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 9	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 10	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 11	*Est. Start Date: **/**/****
	ONCP LY ULYOGLOFIT (Inpatient) Cycles 3+ - Cycle 12	*Est. Start Date: **/**/****

Versioning: Yes

Jira: CST-320598

Protocols: GUPADT

Cycles/PowerPlans: All associated PowerPlans

Changes to the ONCP GU GUPADT Pretreatment Plan:

Baseline Labs phase:

- Added yellow **Clinical Decision Support** note '*If clinically indicated:*' (if not already present).
- Added Sodium Level, Potassium Level, Calcium and Magnesium Level orders.

ONCP GU GUPADT Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 21-Jun-2025			
		Component	Day 1 Future Pending *Est. 21-Jun-2025 08:00:00 Actions ▾
<input checked="" type="checkbox"/>		Prostatic Specific Antigen Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		Testosterone Level Blood, once, Order for future visit	Planned
		If clinically indicated:	
<input type="checkbox"/>		Sodium Level Blood, once, Order for future visit	
<input type="checkbox"/>		Potassium Level Blood, once, Order for future visit	
<input type="checkbox"/>		Calcium Level Blood, once, Order for future visit	
<input type="checkbox"/>		Magnesium Level Blood, once, Order for future visit	

Diagnostic phase:

- New phase added after Diagnostics phase.
- Added yellow **Clinical Decision Support** note: *If clinically indicated:*.
- Added Electrocardiogram 12 Lead.

ONCP GU GUPADT Pretreatment Plan, Diagnostics (Future Pending)			
		If clinically indicated:	
<input type="checkbox"/>		Electrocardiogram 12 Lead	

Changes to the ONCP GU GUPADT LHRH Agonist Option, ONCP GU GUPADT Degarelix Option with Loading Dose and ONCP GU GUPADT Degarelix Option Maintenance Dose Only PowerPlans:

Next Cycle Labs phase:

- **Added** Sodium Level, Potassium Level, Calcium and Magnesium Level orders.

ONCP GU GUPADT LHRH Agonist Option - Cycle 1, Labs (Day 1, 91, 181, 271, 361) (Future Pending) *Est. 21-Jun-2025 08:00 PDT - 361 Days						
Component	Day 1	Day 91	Day 181	Day 271	Day 361	
	Future Pending	Future Pending	Future Pending	Future Pending	Future Pending	
	*Est. 21-Jun-2025 08:00...	*Est. 19-Sep-2025 08:00...	*Est. 18-Dec-2025 08:00...	*Est. 18-Mar-2026 08:00...	*Est. 16-Jun-2026 08:00...	
Actions	Actions	Actions	Actions	Actions	Actions	
If clinically indicated:						
<input type="checkbox"/> Prostatic Specific Antigen Blood, once, Order for future visit						
<input type="checkbox"/> Testosterone Level Blood, once, Order for future visit						
<input type="checkbox"/> Sodium Level Blood, once, Order for future visit						
<input type="checkbox"/> Potassium Level Blood, once, Order for future visit						
<input type="checkbox"/> Calcium Level Blood, once, Order for future visit						
<input type="checkbox"/> Magnesium Level Blood, once, Order for future visit						
For patients on flutamide, every 3 months:						
<input type="checkbox"/> Bilirubin Total Blood, once, Order for future visit						
<input type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit						
<input type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit						

Diagnostic phase:

- **New phase** added after Diagnostics phase.
- **Added** yellow CDS note 'If clinically indicated:'
- **Added** Electrocardiogram 12 Lead.

ONCP GU GUPADT LHRH Agonist Option - Cycle 1, Diagnostics (Future Pending)	
If clinically indicated:	
<input type="checkbox"/>	Electrocardiogram 12 Lead

Versioning: Yes

Jira: CST-320845

Protocols: LYEPOCHR

Cycles/PowerPlans: ONCP LY LYEPOCHR Outpatient

Changes to ONC LY LYEPOCHR (Outpatient) Regimen:

- **Moved** Standing Lab Requisitions for Nadir Monitoring PowerPlan between the Pretreatment Plan and Cycle 1 PowerPlan.

ONC LY LYEPOCHR (Outpatient) (Pending)

▶ Show additional details

+ Add Document Response View Responses

ONCP LY LYEPOCHR (Outpatient) Pretreatment Plan	*Est. Start Date: **/**/****
Start	Skip
ONCP LY LYEPOCHR Standing Lab Requisitions for Nadir Monitoring	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 1	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 2	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 3	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 4	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 5	*Est. Start Date: **/**/****
ONCP LY LYEPOCHR (Outpatient) - Cycle 6	*Est. Start Date: **/**/****

- Rename 'ONCP LY EPOCHR Outpatient Labs' to 'ONCP LY LYEPOCHR Standing Lab Requisitions for Nadir Monitoring'.

ONCP LY LYEPOCHR Standing Lab Requisitions for Nadir Monitoring, Baseline Labs (Future Pending)		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential	Blood, once, Order for future visit
<input checked="" type="checkbox"/> +4 day	<input checked="" type="checkbox"/> CBC and Differential	Blood, once, Order for future visit

Labs phase:

- **Added yellow Clinical Decision Support** note: *Ensure patient has a standing requisition for CBC monitoring twice weekly for nadir monitoring if receiving intrathecal methotrexate on Day 5 (labs within 24 hours).*
- **Unchecked** the CBC and Differential, INR and PTT for Day 4.
- **Updated yellow Clinical Decision Support** note: *If receiving intrathecal methotrexate on Day 1 of next cycle (labs within 72 hours).*
- **Updated yellow Clinical Decision Support** note: *Prior to next cycle:.*
- **Moved** CBC for Day 22 under Clinical Decision Support note and pre-check.
- **Added yellow Clinical Decision Support** note: *If clinically indicated prior to next cycle:.*

ONCP LYEPOCHR (Outpatient) - Cycle 1, Labs (Days 4, 22) (Future Pending) *Est. 21-Jun-2025 08:00 PDT - 25 Days

	Component	Days 4	Days 22
		Future Pending	Future Pending
		*Est. 21-Jun-2025 08:00...	*Est. 09-Jul-2025 08:00...
		Actions ▾	Actions ▾
	Ensure patient has a standing requisition for CBC monitoring twice weekly for nadir monitoring if receiving intrathecal methotrexate on Day 5 (labs within 24 hours)		
<input type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit		
	If receiving intrathecal methotrexate on Day 1 of next cycle (labs within 72 hours)		
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit		
	Prior to next cycle:		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit		Planned
	If clinically indicated prior to next cycle:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Urinalysis Macroscopic (dipstick) Urine, once, Order for future visit		

Versioning: Yes

Jira: CST-320637

Protocols: CNELTZRT

Cycles/PowerPlans: ONCP CN CNELTZRT Concurrent (PO)

Changes:

- **Updated Order Comment** for temozolomide: *Apply standard dose. Pharmacy to confirm with radiation schedule, lab work, and local pharmacy procedures to dispense appropriate weekly/total doses (Max 28 days).*

☒ temozolomide (temozolomide - oncology) 75 mg/m2, PO, qdaily, drug form: cap, dispense qty: 3 week
Apply standard dose. Pharmacy to confirm with radiation schedule, lab work, and local pharmacy procedures to dispense appropriate weekly/total doses (Max 28 days)

Versioning: Yes













Jira: CST-320212

Protocols: CNTEMOZ

Cycles/PowerPlans: ONC CN CNTEMOZ (PO)

Changes:

- **Updated** regimen from 6 cycles to 12 cycles.

ONCP CN CNTEMOZ (PO) Pretreatment Plan		*Est. Start Date: **/**/****
Start		Skip
	ONCP CN CNTEMOZ (PO) - Cycle 1	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 2	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 3	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 4	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 5	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 6	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 7	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 8	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 9	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 10	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 11	*Est. Start Date: **/**/****
	ONCP CN CNTEMOZ (PO) - Cycle 12	*Est. Start Date: **/**/****
		Extend

Versioning: No

Jira: CST-320209

Net New Protocols:

New Protocols:

- ONC GU GUPADT Relugolix Option
- ONCP GU GUPADT Relugolix Option Maintenance Dose Only
- ONCP GU GUPADT Relugolix Option with Loading Dose
- ONC LY LYCLLIV Low/Moderate TLS Risk
- ONC LY LYCLLIV High TLS Risk
- ONCP LY LYCLLIV Pretreatment Plan
- ONCP LY LYCLLIV Cycles 1 and 2 (PO)
- ONCP LY LYCLLIV Cycle 3 (PO)
- ONCP LY LYCLLIV Low/Moderate TLS Risk Ramp-Up Cycle 4 Weeks 1 to 5 (PO)
- ONCP LY LYCLLIV High TLS Risk Ramp-Up Prescriptions Cycle 4 Weeks 1 to 5
- ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Week 1 (Inpatient)
- ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Week 2 (Inpatient)
- ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Weeks 3 to 5 (PO)
- ONCP LY LYCLLIV Post Ramp-Up Cycles 5 to 15 (PO)

Jira: CST-321152, CST-319832

Jira Ticket #	CST-321152, CST-320845, CST-320637, CST-320598, CST-320212, CST-320209, CST-319832, CST-319814, CST-319810, CST-314114
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444